Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pierre Delanaye

Showing results (31-40 of 346) with videos related to

Pageof 35
Sort By:
Annals of Internal Medicine|April 20, 2005
The new Mayo Clinic equation for estimating glomerular filtration ratePierre Delanaye, Jean-Marie Krzesinski
Clinical Journal of the American Society of Nephrology : CJASN|August 20, 2015
Lifetime Risk of CKD: What Does It Really Mean?Pierre Delanaye, Richard J Glassock
Revue Medicale Suisse|August 25, 2022
[Finerenone: a new step on the way to nephroprotection]Pierre Delanaye, Sophie De Seigneux
Kidney International Reports|January 15, 2025
In Defense of Age-Based Estimated GFR Thresholds to Define CKDPierre Delanaye, Bethany J Foster
Expert Review of Endocrinology & Metabolism|December 15, 2021
Understanding the protective effects of SGLT2 inhibitors in type 2 diabetes patients with chronic kidney diseaseAndré J Scheen, Pierre Delanaye
Diabetes & Metabolism|December 15, 2021
Acute renal injury events in diabetic patients treated with SGLT2 inhibitors: A comprehensive review with a special reference to RAAS blockersAndré J Scheen, Pierre Delanaye
Expert Opinion on Pharmacotherapy|November 22, 2018
Preventing and treating kidney disease in patients with type 2 diabetesPierre Delanaye, André J Scheen
Nephron|August 26, 2015
Glomerular Filtration Rate and Aging: Another Longitudinal Study--A Long Time Coming!Pierre Delanaye, Richard J Glassock
Nephron. Clinical Practice|September 22, 2011
Indexing of renal function parameters by body surface area: intelligence or folly?Pierre Delanaye, Jean-Marie Krzesinski
Diabetes & Metabolism|October 1, 2021
The diuretic effects of SGLT2 inhibitors: A comprehensive review of their specificities and their role in renal protectionPierre Delanaye, Andre J Scheen
Pageof 35

Showing results (31-40 of 346) with videos related to

Sort By:
Pageof 35
Annals of Internal Medicine|April 20, 2005
The new Mayo Clinic equation for estimating glomerular filtration ratePierre Delanaye, Jean-Marie Krzesinski
Clinical Journal of the American Society of Nephrology : CJASN|August 20, 2015
Lifetime Risk of CKD: What Does It Really Mean?Pierre Delanaye, Richard J Glassock
Revue Medicale Suisse|August 25, 2022
[Finerenone: a new step on the way to nephroprotection]Pierre Delanaye, Sophie De Seigneux
Kidney International Reports|January 15, 2025
In Defense of Age-Based Estimated GFR Thresholds to Define CKDPierre Delanaye, Bethany J Foster
Expert Review of Endocrinology & Metabolism|December 15, 2021
Understanding the protective effects of SGLT2 inhibitors in type 2 diabetes patients with chronic kidney diseaseAndré J Scheen, Pierre Delanaye
Diabetes & Metabolism|December 15, 2021
Acute renal injury events in diabetic patients treated with SGLT2 inhibitors: A comprehensive review with a special reference to RAAS blockersAndré J Scheen, Pierre Delanaye
Expert Opinion on Pharmacotherapy|November 22, 2018
Preventing and treating kidney disease in patients with type 2 diabetesPierre Delanaye, André J Scheen
Nephron|August 26, 2015
Glomerular Filtration Rate and Aging: Another Longitudinal Study--A Long Time Coming!Pierre Delanaye, Richard J Glassock
Nephron. Clinical Practice|September 22, 2011
Indexing of renal function parameters by body surface area: intelligence or folly?Pierre Delanaye, Jean-Marie Krzesinski
Diabetes & Metabolism|October 1, 2021
The diuretic effects of SGLT2 inhibitors: A comprehensive review of their specificities and their role in renal protectionPierre Delanaye, Andre J Scheen
Pageof 35